Literature DB >> 27404513

Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.

Margaret C Grabb1, Alan J Cross, William Z Potter, James T McCracken.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27404513      PMCID： PMC5007185          DOI： 10.1097/JCP.0000000000000536

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  19 in total

1.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Authors:  Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street
Journal:  Drug Discov Today       Date:  2011-12-29       Impact factor: 7.851

Review 2.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

3.  Public-private partnerships to revitalize psychiatric drug discovery.

Authors:  Linda S Brady; William Z Potter
Journal:  Expert Opin Drug Discov       Date:  2013-12-06       Impact factor: 6.098

Review 4.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

5.  A dearth of new meds.

Authors:  Kenneth I Kaitin; Christopher P Milne
Journal:  Sci Am       Date:  2011-08       Impact factor: 2.142

Review 6.  Novel methods and technologies for 21st-century clinical trials: a review.

Authors:  E Ray Dorsey; Charles Venuto; Vinayak Venkataraman; Denzil A Harris; Karl Kieburtz
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

Review 7.  Antipsychotic occupancy of dopamine receptors in schizophrenia.

Authors:  Magdalena Nord; Lars Farde
Journal:  CNS Neurosci Ther       Date:  2010-12-08       Impact factor: 5.243

8.  Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study.

Authors:  Tatsuo Mori; Kenji Mori; Emiko Fujii; Yoshihiro Toda; Masahito Miyazaki; Masafumi Harada; Toshiaki Hashimoto; Shoji Kagami
Journal:  Brain Dev       Date:  2011-11-17       Impact factor: 1.961

9.  Transient and steady-state auditory gamma-band responses in first-degree relatives of people with autism spectrum disorder.

Authors:  Donald C Rojas; Peter D Teale; Keeran Maharajh; Eugene Kronberg; Katie Youngpeter; Lisa B Wilson; Alissa Wallace; Susan Hepburn
Journal:  Mol Autism       Date:  2011-07-05       Impact factor: 7.509

Review 10.  GABA system dysfunction in autism and related disorders: from synapse to symptoms.

Authors:  Suzanne Coghlan; Jamie Horder; Becky Inkster; M Andreina Mendez; Declan G Murphy; David J Nutt
Journal:  Neurosci Biobehav Rev       Date:  2012-07-25       Impact factor: 8.989
View more
  6 in total

1.  Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.

Authors:  Joshua T Kantrowitz; Daniel C Javitt; Robert Freedman; Pejman Sehatpour; Lawrence S Kegeles; Marlene Carlson; Tarek Sobeih; Melanie M Wall; Tse-Hwei Choo; Blair Vail; Jack Grinband; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2020-02-03       Impact factor: 7.853

2.  Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.

Authors:  Pejman Sehatpour; Daniel C Javitt; Heloise M De Baun; Marlene Carlson; Anna Beloborodova; David H Margolin; Mark B L Carlton; Nicola L Brice; Joshua T Kantrowitz
Journal:  Neuropsychopharmacology       Date:  2021-10-20       Impact factor: 8.294

3.  Redirecting the revolution: new developments in drug development for psychiatry.

Authors:  Linda S Brady; William Z Potter; Joshua A Gordon
Journal:  Expert Opin Drug Discov       Date:  2019-09-23       Impact factor: 6.098

Review 4.  Promises and challenges of human computational ethology.

Authors:  Dean Mobbs; Toby Wise; Nanthia Suthana; Noah Guzmán; Nikolaus Kriegeskorte; Joel Z Leibo
Journal:  Neuron       Date:  2021-06-17       Impact factor: 18.688

5.  A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD.

Authors:  Marijn Lijffijt; Charles E Green; Nicholas Balderston; Tabish Iqbal; Megan Atkinson; Brittany Vo-Le; Bylinda Vo-Le; Brittany O'Brien; Christian Grillon; Alan C Swann; Sanjay J Mathew
Journal:  Front Psychiatry       Date:  2019-12-13       Impact factor: 4.157

6.  Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study.

Authors:  Zhengchao Dong; Michael F Grunebaum; Martin J Lan; Vashti Wagner; Tse-Hwei Choo; Matthew S Milak; Tarek Sobeih; J John Mann; Joshua T Kantrowitz
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.